Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 58.31% is in line with its 3-year average of 56.20%, near the high end of its 3-year range (39.61%–60.62%).
1.66% above its 12-month average of 57.36%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 59.04%.
GROSS MARGIN
58.31%
GROSS MARGIN AVG TTM
57.36%
GROSS MARGIN AVG 3Y
56.20%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.66%
CURRENT VS 3Y AVG
+3.75%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 726 covered companies
CURRENT VS SECTOR MEDIAN
+43.51%
vs the sector median at left
Market Cap
$840.81M
Gross Margin
44.60%
TTM Avg
46.45%
3Y Avg
50.53%
5Y Avg
59.76%
Market Cap
$859.14M
Gross Margin
92.94%
TTM Avg
91.25%
3Y Avg
45.63%
5Y Avg
30.42%
Market Cap
$824.96M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$825.95M
Gross Margin
35.97%
TTM Avg
27.94%
3Y Avg
30.11%
5Y Avg
34.47%
Market Cap
$876.35M
Gross Margin
91.39%
TTM Avg
91.47%
3Y Avg
93.85%
5Y Avg
95.64%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | $844.23M | 58.31% | 57.36% | 56.20% | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $840.81M | 44.60% | 46.45% | 50.53% | 59.76% |
| Alumis Inc. (ALMS)vs › | $847.45M | 88.23% | 42.73% | 21.36% | 21.36% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $859.14M | 92.94% | 91.25% | 45.63% | 30.42% |
| Jade Biosciences, Inc. (JBIO)vs › | $824.96M | 0.00% | 0.00% | 0.00% | 0.00% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $825.95M | 35.97% | 27.94% | 30.11% | 34.47% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $876.35M | 91.39% | 91.47% | 93.85% | 95.64% |
| Ardelyx, Inc. (ARDX)vs › | $812.21M | 93.96% | 87.19% | 88.05% | 90.06% |
| InMode Ltd. (INMD)vs › | $805.46M | 76.52% | 79.43% | 81.57% | 82.72% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $883.79M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
58.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 59.04% |
| 2026-03-31 | 59.50% |
| 2025-12-31 | 58.98% |
| 2025-09-30 | 55.48% |
| 2025-06-30 | 53.80% |
| 2025-03-31 | 50.86% |
| 2024-12-31 | 57.19% |
| 2024-09-30 | 53.36% |
| 2024-06-30 | 53.73% |
| 2024-03-31 | 55.68% |
| 2023-12-31 | 60.62% |
| 2023-09-30 | 39.61% |
